Navigation Links
Study Finds QIAGEN's HPV Test Offers Greater Long-term Protection From Cervical Disease Than the Pap
Date:5/21/2008

HILDEN, Germany, May 21 /PRNewswire-FirstCall/ --

- Research Supports Replacement of Pap With HPV Test as Front-line Screen

Long-term data from a study published in the International Journal of Cancer show that women screened only with a human papillomavirus (HPV) DNA test are half as likely to develop moderate to severe cervical disease over the next six years as those who get only conventional cytology (the Pap "smear"). The research followed nearly 3,000 women age 35 years and older, and assessed their HPV status using QIAGEN's digene(R) HPV Test - the only such test that is both CE-marked in Europe and approved by the U.S. Food and Drug Administration (FDA).

"These results confirm that HPV DNA testing identifies more women with disease than the Pap," says Professor Jack Cuzick, lead author of the May 15 article and professor of epidemiology at the Wolfson Institute of Preventive Medicine, affiliated with Queen Mary's School of Medicine and Dentistry in London. "They add further support to the proposal to use HPV testing as the sole primary screen in women age 35 or older, when the risk of cervical cancer is highest."

Participants were recruited into the study from April 1994 to September 1997 at 40 different general-medicine practices in the United Kingdom. A colposcopy exam and biopsy were used to confirm or rule out the presence of cervical disease after each woman had both the HPV test and a conventional Pap. The sensitivity of the digene HPV Test was 96 percent for disease detected in the first year - substantially higher than the Pap's 82.4 percent. In addition to the HPV test's greater ability to accurately identify women with pre-cancerous cervical cells or cancer, its specificity (the likelihood that women with positive results actually have disease) was similar to that of the Pap.

Study results also showed that the women's risk of developing cervical abnormalities in the future were significantly less when they
'/>"/>

SOURCE Qiagen N V
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Ironwood Pharmaceuticals and Forest Laboratories Announce Presentation of Linaclotide Phase 2b Chronic Constipation Study Results
2. Safety and Efficacy Results Presented From Largest Prospective Controlled Clinical Study of Ulcerative Colitis
3. Annual FIT Testing Detects Colorectal Cancer Two Years Earlier Than Colonoscopy Alone, Study of High-Risk Population Finds
4. Study Analyzed SYMBICORT(R) in Children with Persistent Asthma
5. Omeros Announces Initiation of Patient Enrollment in OMS201 Phase 1 Study
6. BioMarin Initiates Phase 1 Clinical Study of PEG-PAL in PKU
7. Analysis of Ulcerative Colitis (UC) Time to Symptom Resolution Data from Pivotal Study of LIALDA(TM) (mesalamine) Presented at DDW
8. Elesclomol Study Shows Significant Improvement in Progression-Free Survival for Chemotherapy-Naive Patients With Metastatic Melanoma
9. Palatin Technologies Initiates Phase 2 Hypertension Clinical Study With PL-3994
10. Fuisz Tobacco Announces Clinical Study Results for Fuisz Tobacco Sheet Strip; Super Enhanced Bioavailability of Nicotine From Its Tobacco Sheet Strip Supports Efficacy of Low Dose Tobacco Product
11. Delcath Updates Phase III Patient Enrollment as Pivotal Trial Accelerates, Durable Tumor Responses In Phase II Study Also Cited
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/4/2015)... , Sept. 4, 2015  PTC Therapeutics, Inc. ... five recipients of its first-ever global awards program, ... and Empowerment), designed to aid nonprofit organizations that ... (DMD) community. The announcement is made as the ... Duchenne Awareness Day on Monday, September 7, 2015. ...
(Date:9/4/2015)... , Sept. 4, 2015  IGI Laboratories, Inc. ... based specialty generic pharmaceutical company, today announced it ... to the U.S. Food and Drug Administration (FDA) of ... submissions now pending at the FDA to twenty-nine. ... the Company, commented, "We believe our current pipeline of ...
(Date:9/4/2015)... , Sep. 04, 2015 ... http://www.researchandmarkets.com/research/dvzsqg/investigation ) has announced the addition of ... Hyaluronate Market, 2010-2019" report to their ... long-chain polymer containing repeating disaccharide units of ... fluid and cartilage matrix, sodium hyaluronate can ...
Breaking Medicine Technology:PTC Therapeutics Announces Five Winners In Its First-ever Global Duchenne Muscular Dystrophy Patient Group Award 2PTC Therapeutics Announces Five Winners In Its First-ever Global Duchenne Muscular Dystrophy Patient Group Award 3PTC Therapeutics Announces Five Winners In Its First-ever Global Duchenne Muscular Dystrophy Patient Group Award 4IGI Laboratories, Inc. Announces Seventh ANDA Submission Of 2015 2Investigation Report on China's Sodium Hyaluronate Market 2015 2
... - Peregrine's Selective Anti-VEGF Antibodies Inhibited Tumor Growth By, ... 90% In ... Inhibit VEGF Receptor,2 Could , Potentially Have Advantages over Non-Selective Approaches ... Fully Human,Antibody Support , Advancing Peregrine's Anti-VEGF Program towards Clinical Trials,- ...
... AACR Annual Meeting, BLOOMFIELD, N.J., April 16, 2007 ... and in vitro,preclinical data presented in a poster ... Meeting show that ONCONASE,(ranpirnase) significantly inhibits tumor growth ... cells. , In the poster titled "Increased apoptosis ...
Cached Medicine Technology:Data Presented at AACR Meeting Shows Peregrine's Selective,Anti-VEGF Antibodies are as Effective as Avastin(R) in Preclinical,Cancer Models 2Data Presented at AACR Meeting Shows Peregrine's Selective,Anti-VEGF Antibodies are as Effective as Avastin(R) in Preclinical,Cancer Models 3Data Presented at AACR Meeting Shows Peregrine's Selective,Anti-VEGF Antibodies are as Effective as Avastin(R) in Preclinical,Cancer Models 4Data Presented at AACR Meeting Shows Peregrine's Selective,Anti-VEGF Antibodies are as Effective as Avastin(R) in Preclinical,Cancer Models 5Preclinical Data Show Alfacell's Onconase Inhibits Tumor Growth of,Non-Small Cell Lung Cancer, Breast Cancer Cells 2Preclinical Data Show Alfacell's Onconase Inhibits Tumor Growth of,Non-Small Cell Lung Cancer, Breast Cancer Cells 3
(Date:9/4/2015)... ... September 04, 2015 , ... San Francisco cosmetic ... CitiDent. CEREC is a newer method for creating restorations through innovative imaging equipment ... eliminating the need for multiple appointments, CEREC produces restorations with total precision for ...
(Date:9/4/2015)... ... September 04, 2015 , ... Many consumers are looking for a quick and convenient way ... , The patent-pending K Med Cups provide a quick and simple way to brew a ... cold, flu or cough. As a result, they enhance comfort and health. The invention features ...
(Date:9/4/2015)... ... September 04, 2015 , ... ... taking place in Hollywood, Florida October 9-10, 2015 at the Diplomat Resort & ... 2015 symposium are doctors and researchers at the top of their field and ...
(Date:9/4/2015)... ... ... Lalonde Gordon ran a 44.64 seconds scorcher in the third and final ... meters final, with an impressive 44.89 seconds at the 2015 North American, Central American ... August 2015. The 44.64 time is a new NACAC Championship record. , Recent ...
(Date:9/4/2015)... ... September 04, 2015 , ... Yisrayl Hawkins, Pastor and Overseer at The House of Yahweh, has ... involving the Pope’s upcoming trip to the United States. , Yisrayl lays out what he ... the Vatican and society is. Yisrayl also provides the meaning of his own name and ...
Breaking Medicine News(10 mins):Health News:San Francisco Dentist, Dr. Ben Amini, is Now Offering CEREC Technology at CitiDent 2Health News:Redesigned Packaging for Powdered Medicinal Mix Invented by InventHelp® Client (CBA-2637) 2Health News:Integrative Healthcare Symposium Focus On: The Microbiome Conference Program Announced 2Health News:Lalonde Gordon’s Recipe Brings Home the Gold 2Health News:Lalonde Gordon’s Recipe Brings Home the Gold 3Health News:Yisrayl Hawkins Writes Open Letter to Pope Francis In Light of Approaching U.S. Visit 2
... , WASHINGTON, Aug. 31 As Congress prepares ... participating in at least 102 rallies and other events in ... a public health insurance option. , , ... the day Congress returns to Washington, D.C.. They are taking ...
... CHADDS FORD, Pa., Aug. 31 Endo Pharmaceuticals (Nasdaq: ENDP ) ... 2009 on Thursday, Sept. 10, 2009, at 2:40 p.m. EDT. Alan Levin, ... , , The presentation will be webcast live and can ... investors section. , , About Endo ...
... Aug. 31 A new study by Rand Corporation, published ... concludes retail clinics provide quality care at lower costs and ... study was based in part on data from MinuteClinic and ... to provide quality care and lower medical costs, MinuteClinic officials ...
... , , VENTURA, Calif., Aug. 31 ... than to receive." However, when the gift one is giving is ... with more than 97 percent organic aloe vera, receiving and giving ... Founded by Rinaldo and Lalla Brutoco, owners of the manufacturer ...
... , , , ... (the "Company") today announced that, at the Company,s 2009 Annual Meeting ... re-elect by an overwhelming majority all of the Company,s nominees to ... meeting were 63,725,589, representing approximately 56% of the 114,007,240 shares outstanding ...
... men, researchers say , MONDAY, Aug. 31 (HealthDay News) -- ... antigen (PSA) has led to mass over-diagnosis and over-treatment, a ... into use in 1986, federal government data show that the ... risen substantially, said the report in the Aug. 31 online ...
Cached Medicine News:Health News:'Let's Get it Done!' From Coast to Coast, USAction Affiliates Rally This Week for Quality, Affordable Health Care 2Health News:Endo Pharmaceuticals to Present at Thomas Weisel Partners Healthcare Conference 2009 2Health News:MinuteClinic Says Rand Corporation Study in Annals of Internal Medicine Study on Quality, Affordable Care at Retail Clinics Affirms Internal Information 2Health News:MinuteClinic Says Rand Corporation Study in Annals of Internal Medicine Study on Quality, Affordable Care at Retail Clinics Affirms Internal Information 3Health News:It's Better to Give Than to Receive 2Health News:It's Better to Give Than to Receive 3Health News:Healthcare Trust of America, Inc. Announces Results of 2009 Annual Meeting of Stockholders 2Health News:Healthcare Trust of America, Inc. Announces Results of 2009 Annual Meeting of Stockholders 3Health News:Prostate Cancer Over-Diagnosed: Study 2Health News:Prostate Cancer Over-Diagnosed: Study 3
... unique microprocessor controlled shaking incubator that accommodates ... or 384 well format. Speed, temperature and ... and all are displayed on the LCD. ... protective cover. The Millennium 2000 can be ...
Modular flow cytometer with all options....
This unique system combines the analytical power of a research cytometer into a compact, truly walk away, clinical analyzer ergonomically designed to expedite sample throughput....
... The IMMULITE 2000, a continuous random ... of 200 tests per hour, has ... and consolidation in medium- and high-volume ... with its self-explanatory graphical user interface, ...
Medicine Products: